Arzerra Side Effects
Generic Name: ofatumumab
Note: This page contains information about the side effects of ofatumumab. Some of the dosage forms included on this document may not apply to the brand name Arzerra.
Not all side effects for Arzerra may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to ofatumumab: intravenous solution
In addition to its needed effects, some unwanted effects may be caused by ofatumumab (the active ingredient contained in Arzerra). In the event that any of these side effects do occur, they may require medical attention.
If any of the following side effects occur while taking ofatumumab, check with your doctor or nurse immediately:More common
- Black, tarry stools
- bloating or swelling of the face, arms, hands, lower legs, or feet
- blurred vision
- body aches or pain
- chest pain
- cough or hoarseness
- cough producing mucus
- difficult or labored breathing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- ear congestion
- facial swelling
- fast heartbeat
- feeling of warmth
- hives or welts, itching, or skin rash
- increased sweating
- loss of voice
- lower back or side pain
- nasal congestion
- nausea or vomiting
- painful blisters on the trunk of the body
- painful or difficult urination
- pale skin
- rapid weight gain
- rapid, shallow breathing
- redness of the face, neck, arms, and occasionally, upper chest
- runny nose
- sore throat
- tightness in the chest
- tingling of the hands or feet
- troubled breathing
- troubled breathing with exertion
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight gain or loss
- Fast, pounding, or irregular heartbeat or pulse
- pounding in the ears
- slow heartbeat
- Blistering, peeling, or loosening of the skin
- dark urine
- fluid-filled skin blisters
- joint or muscle pain
- light-colored stools
- no blood pressure or pulse
- red skin lesions, often with a purple center
- red, irritated eyes
- sensitivity to the sun
- skin thinness
- stopping of heart
- yellow eyes or skin
Some of the side effects that can occur with ofatumumab may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Back pain
- muscle aches
- redness of the skin
- trouble sleeping
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
- muscle spasms
- pain or tenderness around the eyes and cheekbones
For Healthcare Professionals
Applies to ofatumumab: intravenous solution
General side effects including pyrexia (20%), fatigue (15%), peripheral edema (9%), chills (8%), sepsis (8%), and herpes zoster (6%) have been reported.
A total of 108 patients (70%) experienced bacterial, viral, or fungal infections. A total of 45 patients (29%) experienced grade 3 infections, of which 19 (12%) were fatal.
Infusion reactions occurred in 44% of patients on the day of the first infusion (300 mg), 29% on the day of the second infusion (2,000 mg), and less frequently during subsequent infusions.
Sepsis included sepsis, neutropenic sepsis, bacteremia, and septic shock.
Hematologic side effects including anemia (16%) have been reported.
Out of 108 patients with normal neutrophil counts at baseline, 45 (42%) developed grade 3 neutropenia. Nineteen (18%) developed grade 4 neutropenia. Some patients experienced new onset grade 4 neutropenia over two weeks in duration.
Respiratory side effects including pneumonia (23%), cough (19%), dyspnea (14%), upper respiratory tract infection (11%), bronchitis (11%), nasopharyngitis (8%), and sinusitis (5%) have been reported.
Pneumonia included pneumonia, lung infection, lobar pneumonia, and bronchopneumonia.
Gastrointestinal side effects including diarrhea (18%) and nausea (11%) have been reported.
Rash included rash, macular rash, and vesicular rash.
Dermatologic side effects including rash (14%), urticaria (8%), and hyperhidrosis (5%) have been reported.
Musculoskeletal side effects including back pain (8%) and muscle spasms (5%) have been reported.
Psychiatric side effects including insomnia (7%) have been reported.
Nervous system side effects including headache (6%) have been reported.
Cardiovascular side effects including hypertension (5%), hypotension (5%), and tachycardia (5%) have been reported.
More about Arzerra (ofatumumab)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.